Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Anemia 19Neoplasms 8Breast Neoplasms 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Neoplasms, Plasma Cell 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Ovarian Neoplasms 1Neutropenia 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

tremelimumab 1pegfilgrastim 1durvalumab 1Sunitinib 1Paclitaxel 1Imatinib Mesylate 1Ifosfamide 1Darbepoetin alfa 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Dysgerminoma × Darbepoetin alfa × Clear all
NCT00204633 2009-02-16

Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)

University Hospital Tuebingen

Phase 2 Completed
108 enrolled

Dysgerminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡